Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Primary objective: To investigate the in vivo time course of ruxolitinib in healthy subjects after taking a single oral dose of ruxolitinib phosphate tablets (test preparation, specification: 20 mg, calculated as ruxolitinib) produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (licensed by Qingdao Guoxin Pharmaceutical Co., Ltd.) and ruxolitinib phosphate tablets (reference preparation, trade name: Jakavi®, specification: 20 mg, calculated as ruxolitinib) produced by Novartis Farmacéutica S.A. (licensed by Novartis Europharm Limited) in fasting and postprandial state using a randomized, open, two-period, two-sequence, double-crossover design, and to evaluate the bioequivalence between the preparations in fasting and postprandial state. Secondary objective: To evaluate the safety of the test preparation and reference preparation (trade name: Jakavi®) of ruxolitinib phosphate tablets in healthy subjects.

Primary objective: To evaluate the safety and tolerability of single and multiple intravenous infusions of BG136 for injection in healthy subjects. Secondary objectives: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single and multiple intravenous infusions of BG136 for injection in healthy subjects; To evaluate the safe and effective dose range of BG136 for injection in healthy subjects, and provide a basis for the dosing regimen of Phase II clinical studies; To evaluate the immunogenicity of BG136 for injection in healthy subjects.

Main research purpose: To investigate the single oral administration of 0.5 μg test preparation idecalcidol soft capsule (specification: 0.5 μg/capsule, produced by Chia Tai Pharmaceutical (Qingdao) Co., Ltd.) and the reference preparation idecalcitol under fasting/postprandial conditions. Pharmacokinetic characteristics of Huachol Soft Capsule (trade name: EDIROL®, specification: 0.5 μg/capsule, produced by Chugai Seiko Co., Ltd.) in Chinese adult healthy subjects were evaluated after oral administration in fasting and postprandial states. Bioequivalence of formulations. Secondary study purpose: To evaluate the safety of a single oral dose of 0.5 μg of the test preparation and reference preparation in Chinese adult healthy subjects under fasting/postprandial conditions.